⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727690 | 0.76 | — | — | |
| SCHEMBL3234382 | 0.73 | — | — | |
| SCHEMBL10136440 | 0.71 | — | — | |
| SCHEMBL16982020 | 0.71 | — | — | |
| SCHEMBL15403705 | 0.71 | — | — | |
| SCHEMBL23746600 | 0.69 | — | — | |
| SCHEMBL6994682 | 0.69 | — | — | |
| SCHEMBL12618069 | 0.69 | — | — | |
| SCHEMBL12353967 | 0.69 | — | — | |
| SCHEMBL14048537 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10766990-B2 | Tetrafluoroethylene/hexafluoropropylene copolymers including perfluoroalkoxyalkyl pendant groups and methods of making and using the same | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180066090-A1 | TETRAFLUOROETHYLENE/HEXAFLUOROPROPYLENE COPOLYMERS INCLUDING PERFLUOROALKOXYALKYL PENDANT GROUPS AND METHODS OF MAKING AND USING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2018-03-08 | — | — | US | disclosed |
| EP-2117725-B1 | METHOD FOR FABRICATING LAMINATE NANOMOLDS | LIQUIDIA TECH INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170044290-A1 | STABLE AND ION-CONDUCTIVE FLUOROPOLYMER-BASED ELECTROLYTES | MIDWEST ENERGY GROUP INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2013065878-A1 | METHOD OF FORMING PATTERN AND COMPOSITION FOR CROSSLINKED LAYER FORMATION TO BE USED IN THE METHOD | FUJIFILM CORPORATION (JP) | 2013-05-10 | — | — | WO | disclosed |
| US-20050053552-A1 | Phase shift colloids as ultrasound contrast agents | QUAY STEVEN C (US) | 2005-03-10 | — | — | US | disclosed |
| US-6569404-B1 | Aqueous colloidal suspension, dispersed phase is gas microbubbles of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane or sulfur hexafluoride; fluorinated amphiphile for stabilizing microbubbles | AMERSHAM HEALTH A/S (NO) | 2003-05-27 | — | — | US | disclosed |
| US-6245319-B1 | Colloidal dispersions of perfluoropentane | SONUS PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| EP-0680341-B1 | PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS | SONUS PHARMA INC (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1038535-A2 | Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents | SONUS PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-5876696-A | Composition comprising a fluorine containing surfactant and perfluoropentane for ultrasound | SONUS PHARMACEUTICALS, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5558853-A | WATER IMMISCIBLE FLUORINE COMPOUND | SONUS PHARMACEUTICALS (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0680341-A1 | PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS | SONUS PHARMACEUTICALS, INC. (US) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994016739-A1 | PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS | SONUS PHARMACEUTICALS, INC. (US) | 1994-08-04 | — | — | WO | disclosed |